Managed Care


Rand Questions Off-label Use

MANAGED CARE October 2011. © MediMedia USA
News and Commentary

Rand Questions Off-label Use

MANAGED CARE October 2011. ©MediMedia USA

There is insufficient evidence that atypical antipsychotics are effective in treating eating disorders, substance abuse, and insomnia — medical conditions that these drugs were not approved to treat — according to a new Rand study.

Other off-label conditions do respond, though. Evidence supports the effectiveness of some atypical antipsychotics in reducing symptoms of generalized anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, and behavioral symptoms in elderly patients with dementia, although significant side effects were noted.

“The use of atypical antipsychotic medications has spread rapidly beyond the illnesses they ... were developed to treat,” says lead author Alicia Ruelaz Maher, MD, a psychiatrist and researcher at Rand. “While evidence suggests the drugs help reduce symptoms for some off-label illnesses, we found a lack of evidence for others.”

The findings are published in the September edition of the Journal of the American Medical Association.


4th Partnering With ACOs Summit Los Angeles, CA October 27–28, 2014
PCMH & Shared Savings ACO Leadership Summit Nashville, TN November 3–4, 2014
2014 Annual HEDIS® and Star Ratings Symposium Nashville, TN November 3–4, 2014
Medicare Risk Adjustment, Revenue Management, & Star Ratings Fort Lauderdale, FL November 12–14, 2014
World Orphan Drug Congress Europe 2014 Brussels, Belgium November 12–14, 2014
Healthcare Chief Medical Officer Forum Alexandria, VA November 13–14, 2014
Home Care Leadership Summit Atlanta, GA November 17–18, 2014
HealthIMPACT Southeast Tampa, FL January 23, 2015